YS Biopharma Co Ltd YS

NAS: YS | ISIN: KYG9845F1090   24/05/2024
1,020 USD (+12,45%)
(+12,45%)   24/05/2024

24 mei 2024 · YS Biopharma Announces Name Change to LakeShore Biopharma · Persbericht

21 mei 2024 · YS Biopharma Announces Results of Extraordinary General Meeting · Persbericht

7 mei 2024 · YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer · Persbericht

29 april 2024 · YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule · Persbericht

19 april 2024 · YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 · Persbericht

18 april 2024 · YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine · Persbericht

16 april 2024 · YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 · Persbericht

9 april 2024 · YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine · Persbericht

3 april 2024 · YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility · Persbericht

5 maart 2024 · YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries · Persbericht

22 februari 2024 · YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024 · Persbericht

18 februari 2024 · /C O R R E C T I O N -- YS Biopharma Co., Ltd./ · Persbericht

17 februari 2024 · YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting · Persbericht

14 februari 2024 · YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance · Persbericht

14 februari 2024 · YS Biopharma Announces Appointment of New Directors · Persbericht

12 februari 2024 · YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd. · Persbericht

9 februari 2024 · YS Biopharma Announces US$40 Million Private Placement Financing · Persbericht

9 februari 2024 · Shareholders of YS Biopharma Announce an Extraordinary General Meeting · Persbericht

22 januari 2024 · YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024 · Persbericht

8 januari 2024 · YS Biopharma Announces Changes to its Board Committees · Persbericht

Mijn selecties